and escape the effects of therapeutic agents; it also promotes tumor aggressiveness. There is increasing evidence that an inflammatory environment promotes the retrodifferentiation of tumor cells into stem or progenitor cells; this could account for the low efficacies of some chemotherapies and the high rates of cancer recurrence. Increasing our understanding of the signaling network that connects inflammation with retrodifferentiation could identify new therapeutic targets, and lead to combined therapies that are effective against highly heterogeneous tumors.
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Cancer heterogeneity and retrodifferentiation
An important concern regarding solid tumors arises from phenotypical and functional heterogeneities that make the eradication of all tumor cells difficult, and allow cancer recurrence from untargeted cells. Heterogeneity is a well-known hallmark of hepatocellular carcinoma (HCC) and occurs even within the same nodule 1 . It results from the cellular origin of HCC and the landscape of genetic/epigenetic alterations. Such alterations rely on both the intrinsic genomic instability of tumor-initiating cells and stimuli from the tumor environment, which constitute an additional source of genetic instability that promotes oncogenic events 2, 3 .
Indeed, fibrosis and extracellular matrix remodeling, mechanical stress, hypoxia, acidosis, metabolic changes, immune cell infiltration and even chemotherapy-induced inflammation contribute to the generation of chronic inflammation that exerts a selective pressure. Such a selective pressure induces a high cellular turnover, overcomes DNA repair mechanisms and contributes to malignant transformation. In addition to the accumulation of stochastic genetic/epigenetic changes in tumor cells, the identification of stem cells in various tissues raises the hypothesis that a subset of cells with stem/progenitor cell features and tumorigenic capacity contributes to tumor heterogeneity 4 . Similarities between tumors and embryonic tissues also suggest that tumors can arise from an interrupted differentiation of a population of stem cells 5 .
Abnormal stem/progenitor cells, called CSCs, display high metastatic potential and radiotherapy/chemotherapy resistance, resulting in poor outcomes for patients. CSCs, which share many features with normal stem cells, have the ability to self-renew by symmetric division and to give rise to proliferating progenitors and more differentiated dividing cells that are not tumorigenic by asymmetric division. The paradigm for the CSC hierarchical model is that once cells have left the stemness state, they cannot revert back. Although some studies have provided evidence for the CSC hierarchical model in some cancers including, HCC, the M A N U S C R I P T
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generalization of this unidirectional model can be questioned. Indeed, it does not consider cell plasticity, which includes the ability to undergo retrodifferentiation (i. 23 . Thus, it can be expected that cancer may be derived from the malignant transformation of stem/progenitor cells or mature cells and that bi-directional plasticity between CSC and non-CSC populations allows non-CSCs to adapt to stress, escape cell death and replenish the CSC pool ( Figure 1 ).
Moreover, cell plasticity could reconcile hierarchical and stochastic models, considering that the capacity of retrodifferentiation may be either inherited or acquired 24 . Finally, these observations must be analyzed in the light of successful ex vivo reprogramming of 
Inflammation and retrodifferentiation
The liver is especially exposed to chronic infections or environmental insults (e.g., alcohol, obesity), and the resulting unresolved inflammation state is associated with an increased risk of cancer. Therefore, up to 80% of HCCs occur during the course of chronic liver diseases (hepatitis, alcoholic or non-alcoholic steatohepatitis) 26 . Consistently, the presence of proinflammatory cytokines in peritumoral tissues or systemic circulation contributes to tumor progression and is associated with a higher risk of recurrence and poor prognosis in HCC 27,28 .
Significant efforts have been made over the past few years to unravel cellular crosstalks within the HCC niche. They provided new data that improved understanding of the molecular mechanisms that generate and maintain a pro-inflammatory environment in the liver 29, 30 . The Together, these soluble factors promote cell invasion and migration by generating a more permissive microenvironment 39 . Importantly, we showed that TNF-, IL-6 and TGF-trigger the retrodifferentiation of tumor-derived hepatocytes into stem/progenitor cells 17 promote EMT, which contributes to invasion and metastases through the inhibition of cadherin expression [40] [41] [42] . TNF-α also activates the Wnt/β-catenin signaling, which is involved in both normal and cancer stem cell functions 43 . In breast cancer cells, TNF-exposure and SNAI2 overexpression induce partial nuclear localization of -catenin, promoting the acquisition of a stem cell-like phenotype 41 . Importantly, it has been shown that TNF- demonstrated that -catenin is essential for the NANOG-mediated effects. In turn, NANOG represses DKK1, an important negative regulator of the Wnt pathway, leading indirectly tocatenin activation. As reported in IEC, the retrodifferentiation of tumor-derived hepatocytes leads to the nuclear translocation of -catenin and subsequent induction of -catenin-target genes such as LGR5, NANOG and OCT4 15, 17 . Importantly, the expression of NANOG in liver CSCs was shown to control mitochondrial metabolism reprogramming that presumably contributes to the progression of liver cancer 49 . Indeed, NANOG represses oxidative phosphorylation, reactive oxygen species (ROS) generation and activates fatty-acid oxidation to sustain CSC renewal and chemoresistance.
Other cytokines such as CCL22, TGF-and IL-6 TAM-derived cytokines contribute to the EMT and to the acquisition of stemness phenotype by hepatic tumor cells 50 . Using the HepaRG cells, our laboratory unraveled some crosstalks between cytokines involved in the retrodifferentiation of hepatic tumor cells 17 . We showed that both IL-6 and TGF-1/TGF-2 
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Another key player in the retrodifferentiation process is TGF-, which induces EMT (see for review 57 ). TGF-cooperates with signaling pathways involved in the maintenance of stem cell niche such as Wnt, Hedgehog, NOTCH and RAS to induce EMT 58 . In agreement, TGFwas shown to induce the retrodifferentiation of cancer cells to CSCs 59 and to trigger the retrodifferentiation of tumor-derived hepatocytes along with IL-6 and TNF- 17 . In colon cancer, TGF-increases the production of IL-11 by CAFs, which enables the survival and proliferation of IL-11R -expressing colon cancer cells at metastatic sites 60 . However, TGFeffects are contextual and ambivalent as it can exert both anti-and pro-tumorigenic functions. cytokines. However, given the tight coupling between inflammation and protective immune response, these strategies may result in an increased risk of infection. Moreover, we have to keep in mind that TNF-α and IL-6 are priming factors for the liver regeneration. Thus, attenuation, rather than inhibition, of inflammatory response should be considered.
In that respect, clinical trials conducted using TNF-α blockers (infliximab, etanercept) or anti-IL-6 mAb (siltuximab) only achieved limited activity. Recently, particular attention was paid to NF-B pathway, which is strongly activated during the retrodifferentiation process.
Marquardt et al. showed that the IKK inhibitor curcumin triggers selective CSC depletion through NF-B-mediated histone deacetylase (HDAC) inhibition in hepatoma cells 44 .
Interestingly, co-administration of class I/II HDAC inhibitor trichostatin sensitized resistant cell lines to curcumin. Likewise, we observed that trichostatin inhibited the crosstalk between activated HSC and tumor-derived hepatocytes leading to a tumor permissive environment, but also to an amplification of the retrodifferentiation program that increases the stem/progenitor cell pool 17, 39 . In the same way, inhibition of the NF-B pathway by disulfiram prevents TGF--induced EMT and stem-like features in breast cancer 63 .
Targeting the Wnt/ catenin pathway also appears as a promising strategy and inhibitors are currently under investigation. A study combining ipafricept (FZD8-Fc fusion protein) and sorafenib in HCC is still recruiting (clinical trial NCT02069145). Other signaling pathways involved in stem cell behavior, such as Sonic/hedgehog or Notch, constitute interesting targets. Vismodegib, a smoothened antagonist, was shown to decrease tumor growth in HCC through an inhibition of proliferation of the side population 64 and to significantly attenuate HCC growth in mice 65 (clinical trial NCT01546519). Notch inhibitor RO4929097 also efficiently decreased tumor growth and prevented HCC and cholangiocarcinoma development in Pten null mice, suggesting that it may be useful in liver cancer 66 .
At the same time, the multifactorial antidiabetic drug metformin showed interesting antineoplastic effects. AMPK-induced NF-κB inhibition 67 and NANOG downregulation through JNK pathway were proposed as possible mechanisms 68 . Alternatively, in the context of cirrhosis, a prolonged metformin exposure was shown to inhibit the receptor for advanced glycation end product (RAGE), a well-known driver of chronic inflammation, in a rat model 68 . This caused decreased expression of inflammatory and fibrotic mediators within the surrounding tissue, starving hepatic stem/progenitor cells from pro-oncogenic stimuli.
Therefore, an early administration of metformin in the course of cirrhosis may prevent HCC development by reducing the tumor-promoting inflammation.
As mentioned above, retrodifferentiation is associated with metabolic reprogramming and hepatic CSCs display alterations of oxidative phosphorylation and fatty-acid elongation that contribute to chemoresistance 49 . Metabolism reprogramming and high levels of detoxifying systems are hallmarks of CSCs that help with adaptation to the microenvironment and contribute to tumor aggressiveness. These acquired metabolic specificities could be Achilles heel of CSCs. In agreement, metformin, which interferes with the energetic metabolism of the cell, also significantly reduces the number of CSCs in HCC through the inhibition of the mTor pathway 69 . Similarly, the restoration of oxidative phosphorylation and/or inhibition of fatty-acid elongation by overexpression of genes involved in these functions abrogates sorafenib resistance and reduces tumor growth in a CSC xenograft mouse model 49 .
Disulfiram, an inhibitor of the detoxifying aldehyde dehydrogenase 1 (ALDH1), was also shown to suppress anchorage-independent sphere formation and to reduce the number of CSCs in HCC (clinical trial NCT00742911) 70 . One more option to counteract the detoxification mechanisms of CSC is to inhibit ATP-binding cassette (ABC) transporters. The third generation of drug efflux pump inhibitors, which have a selective affinity for the ABC subfamilly B member 1 is currently under investigation as CSC-sensitizing drugs 71 .
Differentiating agents could also be useful for resensitizing CSCs to conventional chemotherapies 66 . As an example, miR-148a is proposed to restore hepatic cell differentiation through IKKα/NUMB/NOTCH pathway inhibition. Finally, identification of CSC surface markers (including CD133, CD24, CD44 and LGR5 for liver CSCs) allows the immunotargeting of CSCs by mAb as well as drug delivery or redirected T-cell cytotoxicity.
Anti-CD44 antibody-mediated liposomal nanoparticles loaded with doxorubicin were assessed in preclinical studies for HCC 72 . Meanwhile, a bispecific anti-CD3/CD133 antibody was shown to increase the cytotoxicity against hepatic (Hep3B) cancer cells mediated by immune effector cells 73 .
High cell plasticity is now a widely accepted concept. 
